(545.8) Pentadecapeptide BPC 157 Anti-Ulcer Effect After Stomach Perforation also Opposed the Intracranial Hypertension (Superior Sagittal Sinus), Portal and Caval Hypertension and Aortal Hypotension

Poster Board Number: B191

Antonija Duzel (School of Medicine University of Zagreb), Ivan Krezic (School of Medicine University of Zagreb), Helena Zizek (School of Medicine University of Zagreb), Eva Lovric (School of Medicine University of Zagreb), Slaven Gojkovic (School of Medicine University of Zagreb), Marijan Tepes (School of Medicine University of Zagreb, General Hospital Nasice, Faculty of Dental Medicine and Health Osijek, School of Medicine University of Split), Ante Tvrdeic (School of Medicine University of Zagreb), Anita Skrtic (School of Medicine University of Zagreb), Alenka Boban Blagaic (School of Medicine University of Zagreb), Sven Seiwerth (School of Medicine University of Zagreb), Predrag Sikiric (School of Medicine University of Zagreb)

We report that rat stomach perforation (surgery with 5-mm diameter metal needle on the ventral side in the prepyloric area) induced a defect that would not heal. Also, stomach perforation rapidly induced the intracranial hypertension (superior sagittal sinus), portal and caval hypertension and aortal hypotension. Stable gastric pentadecapeptide BPC 157 largely attenuated or eliminated these pressure disturbances. Finally, BPC 157 completely healed stomach defect. Previously, BPC 157 largely attenuated or even eliminated the consequences of Budd-Chiari syndrome in rats, in particular, portal and caval hypertension and aortal hypotension, and then, huge thrombosis in both veins and arteries, and multiple organ dysfunction syndrome, heart, lung, liver, kidney and gastrointestinal lesions.  These beneficial effects may relieve a Virchows triad situation that may be commonly presented as well as counteracted (i.e.,duodenal venous congestion lesions (World J Gastroenterol 2018), perforated cecum (World J Gastroenterol 2018), bile duct ligation induced liver cirrhosis and portal hypertension (Eur J Pharmacol 2109), Pringle maneuver, ischemia, reperfusion (World J Hepatol  2020), and suprahepatic occlusion of the inferior caval vein (Budd-Chiari-syndrome) (World J Gastrointest Pathophysiol 2020)). Likewise, given in reperfusion, after clamping of the common carotid arteries, BPC 157 counteracted stroke (i.e., both early and delayed neural hippocampal damage, achieving also full functional recovery)  (Brain Behav 2020). Methods. Therapy (BPC 157 (10 µg or 10 ng/kg) or saline (5 ml/kg)) was given intragatrically, at 1 min after stomach perforation. At 5 min after stomach perforation, as described before (World J Hepatol  2020), recordings were made in deeply anesthetized rats. Briefly, a cannula (BD Neoflon™ Cannula) was connected to a pressure transducer (78534C MONITOR/ TERMINAL; Hewlett Packard, USA) inserted into the superior sagittal sinus, and portal vein, and inferior vena cava, and abdominal aorta at the level of the bifurcation. We used  five minutes  recording. For superior sagittal sinus pressure recording, we made a single burr hole in the rostral part of the sagittal suture, above the superior sagittal sinus, and cannulated superior sagittal sinus anterior part by Braun intravenous cannulas, and then, in laparatomized rats, we recorded portal vein, inferior vena cava and abdominal aorta pressure. Results. Without therapy, the severely increased intracranial hypertension (10±2 mmHg in superior sagittal sinus), portal (33±4 mmHg) and caval (28±3 mmHg) hypertension and aortal hypotension (59±3 mmHg) occurred rapidly. Both BPC 157 regimens markedly counteracted intracranial hypertension (-6±2 mmHg in superior sagittal sinus), portal (6±2 mmHg) and caval (5±2 mmHg) hypertension and aortal hypotension (81±3 mmHg) (i.e., 10 ng). Conclusion. BPC 157 anti-ulcer effect also opposed the intracranial hypertension (superior sagittal sinus), portal and  caval hypertension and aortal hypotension.

University of Zagreb Grant number 099